Premium
Does HLA‐B*2706 protect against ankylosing spondylitis? A meta‐analysis
Author(s) -
Van GAALEN Floris Alexander
Publication year - 2012
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/j.1756-185x.2011.01676.x
Subject(s) - ankylosing spondylitis , hla b27 , hla b , meta analysis , medicine , human leukocyte antigen , population , odds ratio , immunology , traditional medicine , antigen , environmental health
The human leukocyte antigen (HLA)‐B*2706 is a relatively rare subtype of HLA‐B27. In contrast to most HLA‐B27 subtypes, some studies have reported HLA‐B*2706 to be protective against ankylosing spondylitis (AS). A systematic review and a meta‐analysis of available studies was performed to investigate the association of HLA‐B*2706 with AS. After literature review a random effect meta‐analysis was performed. No studies were found comparing the frequency of HLA‐B*2706 in AS patients and controls. Meta‐analysis of seven studies using HLA‐B27‐positive AS patients and controls showed a protective effect of HLA‐B*2706 on development of AS in HLA‐B27 individuals (odds ratio = 0.128, 95% CI = 0.043–0.378, P < 0.001). The results of the meta‐analysis of HLA‐B*2706 in HLA‐B27‐positive patients and controls is preliminary evidence of a protective effect of HLA‐B*2706 against AS in the population. There is a clear need for additional studies on HLA‐B*2706 in AS. Due to the fact that HLA‐B*2706 is more or less restricted to Southeast Asia, researchers in this part of the world may have an essential role in performing these studies.